436
Views
0
CrossRef citations to date
0
Altmetric
Articles/Brief Reports

Immunoglobulin G/immunoglobulin M autoantibody ratios in incomplete systemic lupus erythematosus

ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 207-216 | Received 22 Aug 2023, Accepted 19 Feb 2024, Published online: 20 Mar 2024

References

  • Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, Pons-Estel G, et al. Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. Nat Rev Rheumatol 2021;18:9–21.
  • Lambers WM, Westra J, Jonkman MF, Bootsma H, de Leeuw K. Incomplete systemic lupus erythematosus: what remains after application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria? Arthritis Care Res 2020;72:607–14. doi:10.1002/acr.23894
  • Samnaliev M, Barut V, Weir S, Langham J, Langham S, Wang X, et al. Health-care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: a real-world observational retrospective cohort analysis. Rheumatol Adv Pract 20216;5:rkab071. doi:10.1093/rap/rkab071
  • Lambers WM, Westra J, Bootsma H, de Leeuw K. From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers. Semin Arthritis Rheum 2021:51:43–8. doi:10.1016/j.semarthrit.2020.11.006
  • Olsen NJ, Li Q-Z, Quan J, Wang L, Mutwally A, Karp DR. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther 2012;14:R174. doi:10.1186/ar3927
  • Vilá LM, Mayor AM, Valentín AH, García-Soberal M, Vilá S. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus 2000;9:110–15. doi:10.1191/096120300678828073
  • Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526–33. doi:10.1056/NEJMoa021933
  • Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011;13:R30. doi:10.1186/ar3258
  • Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 2000;97:1184–9. doi:10.1073/pnas.97.3.1184
  • Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobulin (Ig) M predisposes to development of IgG autoantibodies. J Exp Med 2000;191:1253–8.
  • Olsen NJ, Karp DR. Autoantibodies and SLE: the threshold for disease. Nat Rev Rheumatol 2014;10:181–6. doi:10.1038/nrrheum.2013.184
  • Witte T. IgM antibodies against dsDNA in SLE. Clin Rev Allergy Immunol 2008;34:345–7. doi:10.1007/s12016-007-8046-x
  • Pisetsky DS. Anti-DNA antibodies - Quintessential biomarkers of SLE. Nat Rev Rheumatol 2016;12:102–10. doi:10.1038/nrrheum.2015.151
  • Li Q-Z, Zhou J, Wandstrat AE, Carr-Johnson F, Branch V, Karp DR, et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol 2007;147:60–70. doi:10.1111/j.1365-2249.2006.03251.x
  • Villalta D, Bizzaro N, Bassi N, Zen M, Gatto M, Ghirardello A, et al. Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PLoS One 2013;8:e71458.
  • Förger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 2004;13:36–44.
  • Jia Y, Zhao L, Wang C, Shang J, Miao Y, Dong Y, et al. Anti-double-stranded DNA isotypes and anti-C1q antibody improve the diagnostic specificity of systemic lupus erythematosus. Dis Markers 2018;2018:4528547. doi:10.1155/2018/4528547
  • Petri M, Orbai AM, Alarcõn GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86. doi:10.1002/art.34473
  • Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MGE, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958–67. doi:10.1002/art.20798
  • Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208. doi:10.1016/j.jbi.2019.103208
  • Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.
  • Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017;76:9–16. doi:10.1136/annrheumdis-2016-210571
  • Witte T, Hartung K, Sachse C, Matthias T, Fricke M, Deicher H, et al. IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. Rheumatol Int 1998;18:85–91. doi:10.1007/s002960050063
  • Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol 2022;18:575–90. doi:10.1038/s41584-022-00826-z
  • Q-Z L, Zhou J, Lian Y, Zhang B, Branch VK, Carr-Johnson F, et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol 2010;159:281–91.
  • Bootsma H, Spronk PE, Ter Borg EJ, Hummel EJ, De Boer G, Limburg PC, et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation. Ann Rheum Dis 1997;56:661–6. doi:10.1136/ard.56.11.661
  • Amendt T, Yu P. TLR7 and IgM: dangerous partners in autoimmunity. Antibodies (Basel) 2023;12:4. doi:10.3390/antib12010004
  • Chong BF, Tseng L-C, Lee T, Vasquez R, Li QZ, Zhang S, et al. IgG and IgM autoantibody differences in discoid and systemic lupus patients. J Invest Dermatol 2012;132:2770–9.
  • Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 2010;10:778–86. doi:10.1038/nri2849
  • Grönwall C, Hardt U, Gustafsson JT, Elvin K, Jensen-Urstad K, Kvarnström M, et al. Depressed serum IgM levels in SLE are restricted to defined subgroups. Clin Immunol 2017;183:304–15. doi:10.1016/j.clim.2017.09.013
  • Silverman GJ, Vas J, Grönwall C. Protective autoantibodies in the rheumatic diseases: lessons for therapy. Nat Rev Rheumatol 2013;9:291–300. doi:10.1038/nrrheum.2013.30
  • Reijm S, Kissel T, Stoeken-Rijsbergen G, Slot LM, Wortel CM, van Dooren HJ, et al. Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load. Arthritis Res Ther 2021;23:230. doi:10.1186/s13075-021-02609-5
  • Hirano Y, Iwata H, Tsujuwaki M, Mai S, Mai Y, Imafuku K, et al. Super-resolution imaging detects BP180 autoantigen in immunoglobulin M pemphigoid. J Dermatol 2022;49:374–8. doi:10.1111/1346-8138.16260